3sbio | our field-银河电玩城

in 2005, tpiao was listed and has been approved by the nmpa for two indications that are the treatment of chemotherapy-induced thrombopenia (approved in 2005) and immune thrombocytopenia (itp) (approved in 2010), which is included in the national medical insurance catalogue as a category b drug of western medicine.

cipterbin was formally approved in june 2020 as the first innovative anti-her2 monoclonal antibody in china with the engineered fc region, optimized production process and a stronger adcc effect. research showed that in combination with chemotherapy drugs, it can significantly reduce the risk of disease progression in patients with her2-positive metastatic breast cancer, improve the objective response rate, and prolong the progression-free survival of the patients.

in 1998, epiao was marketed with approval of the nmpa, which was the first rhepo products marketed in china. since 2002, it has been the leading brand of china’s erythropoin market. it is included in the national medical insurance catalogue as a category b drug.

in april 1995, intefen was approved to be manufactured by nmpa.in december 1995, intefen was launched and is included in the national medical insurance catalogue as a category b drug.

in june 1995, nmpa production approval documents were obtained for inleusin. this product was launched in march 1996 and is included in the national medical insurance catalogue as a category b drug.

yisaipu was marketed in 2005 and is the first antibody fusion protein medicine marketed in the rheumatism field of china. 3 kinds of indications were approved by the nmpa: treatment of rheumatoid arthritis (approved in 2005), ankylosing spondylitis and psoriasis (approved in 2007). it is included in the national medical insurance catalogue as a category b drug of western medicine.

nmpa production approval documents were obtained for sepo in 2001. it was listed in 2002 and is included in the national medical insurance catalogue as a category b drug. in 2014, sepo was rated as famous trademark by guangdong province administration for industry & commerce.

on october 11, 2016, we have entered into an exclusive license agreement with astrazeneca to obtain the commercial rights of byetta in china, which are valid for 20 years.

sparin was approved by the nmpa and listed in 2002. low-molecular-weight heparin calcium is derived from depolymerization of standard heparin. compared to standard heparin, low-molecular-weight heparin calcium has the advantages of lower side effects and more predictable anticoagulant response.

mendi-minoxidil tincture, which was certified by nmpa in 2001, belongs to otc for hair loss and external use. it is the first product of the same kind in china. the national patent number is zl200510115120.7. minodil, the main ingredient of minodil, is approved by the fda of the united states for external use in the treatment of hair loss, which is widely recognized by the medical community.

treatment of iron-deficiency anemia

qiming ke li is an exclusive formula of tcm, indicated for the treatment of type 2 diabetic retinopathy. it is the project achievement of science and technology development during the “9th five-year plan” and “10th five-year plan” and support plan during the “11th five-year plan” and was identified as a national protected traditional chinese medicine by the china food and drug administration in 2013. qiming ke li is the first nmpa-approved new chinese medicine for treatment of diabetic retinopathy and is included in the national medical insurance catalogue as a category b drug of chinese patent medicine.

xenopax is suitable for prevention of acute rejection after renal transplantation, which can be combined with the routine immunosuppression regime to significantly improve the survival rate of transplanted organs and the quality of life of patients.

on may 16, 2017, the company signed an exclusive license agreement with lilly china, obtaining the commercialization rights for insulin product humulin in china.